Oncotarget

Research Papers:

PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells

Alison Yeomans _, Elizabeth Lemm, Sarah Wilmore, Breeze E. Cavell, Beatriz Valle-Argos, Sergey Krysov, Marina Sanchez Hidalgo, Elodie Leonard, Anne E. Willis, Francesco Forconi, Freda K. Stevenson, Andrew J. Steele, Mark J. Coldwell, Graham Packham

Metrics: PDF 429 views  |   HTML 264 views  |   ?  


Abstract

Alison Yeomans1, Elizabeth Lemm1, Sarah Wilmore1, Breeze E. Cavell1,6, Beatriz Valle-Argos1, Sergey Krysov1,9, Marina Sanchez Hidalgo1,7, Elodie Leonard1,8, Anne E. Willis2, Francesco Forconi3,4, Freda K. Stevenson1, Andrew J. Steele1, Mark J. Coldwell5, Graham Packham1

1Cancer Research UK Centre, Faculty of Medicine, University of Southampton, Southampton, UK

2MRC Toxicology Unit, Leicester, UK

3Haematology Oncology Group, Cancer Sciences Unit, Cancer Research UK Centre, University of Southampton, Faculty of Medicine, Southampton, UK

4Department of Haematology, University Hospital Southampton NHS Trust, Southampton, UK

5Centre for Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, UK

6Current Address: Public Health England, Porton Down, Salisbury, UK

7Current Address: Department of Pharmacology, Faculty of Pharmacy, University of Seville, Seville, Spain

8Current Address: XPE Pharma and Science, Wavre, Belgium

9Current Address: Bart’s Cancer Institute, Queen Mary University of London, London, UK

Correspondence to:

Alison Yeomans, email: A.M.Yeomans@soton.ac.uk

Keywords: phenethylisothiocyanate, mRNA translation, eIF2α, mTORC1, MYC

Received: February 15, 2016     Accepted: July 27, 2016     Published: August 27, 2016

ABSTRACT

Increased mRNA translation drives carcinogenesis and is an attractive target for the development of new anti-cancer drugs. In this work, we investigated effects of phenethylisothiocyanate (PEITC), a phytochemical with chemopreventive and anti-cancer activity, on mRNA translation. PEITC rapidly inhibited global mRNA translation in human breast cancer-derived MCF7 cells and mouse embryonic fibroblasts (MEFs). In addition to the known inhibitory effects of PEITC on mTORC1 activity, we demonstrate that PEITC increased eIF2α phosphorylation. PEITC also increased formation of stress granules which are typically associated with eIF2α phosphorylation and accumulation of translationally stalled mRNAs. Analysis of genetically modified MEFs demonstrated that optimal inhibition of global mRNA translation by PEITC was dependent on eIF2α phosphorylation, but not mTORC1 inhibition. We extended this study into primary leukemic B cells derived from patients with chronic lymphocytic leukaemia (CLL). CLL cells were stimulated in vitro with anti-IgM to mimic binding of antigen, a major driver of this leukemia. In CLL cells, PEITC increased eIF2α phosphorylation, inhibited anti-IgM-induced mTORC1 activation and decreased both basal and anti-IgM-induced global mRNA translation. PEITC also inhibited transcription and translation of MYC mRNA and accumulation of the MYC oncoprotein, in anti-IgM-stimulated cells. Moreover, treatment of CLL cells with PEITC and the BTK kinase inhibitor ibrutinib decreased anti-IgM-induced translation and induced cell death to a greater extent than either agent alone. Therefore, PEITC can inhibit both global and mRNA specific translation (including MYC) via effects on multiple regulatory pathways. Inhibition of mRNA translation may contribute to the chemopreventive and anti-cancer effects of PEITC.

Author Information

Alison Yeomans
Primary Contact  _

Elizabeth Lemm

Sarah Wilmore

Breeze E. Cavell

Beatriz Valle-Argos

Sergey Krysov

Marina Sanchez Hidalgo

Elodie Leonard

Anne E. Willis

Francesco Forconi

Freda K. Stevenson

Andrew J. Steele

Mark J. Coldwell

Graham Packham


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11655